Daniel Lamarre, PhD
Dr Lamarre has completed his doctoral studies in biochemistry at the Université de Sherbrooke (Canada) and postdoctoral training in immunology at IRCM (Montreal) and Genentech (San Francisco). He then joined Boehringer Ingelheim R&D Canada, where he contributed to research programs in the areas of HIV and HCV infectious diseases. As the HCV therapeutic head, he established a leading position world-wide with the discovery of BILN 2061 (ciluprevir), the first-in-class antiprotease compound ever tested in human for the treatment of HCV infection. Over the last 25 years, he made significant contributions in deciphering molecular aspects of virus-host interactions and identifying regulators of the intrinsic innate immune response through system biology approaches. In 2003, he began his academic career at the Université de Montréal as full professor and co-founder of IRIC - one of the first System Biology Research Institute in Canada. Recently, he joined the Center for Systems Immunology (CSI) at Case Western Reserve University where he focuses his research on engineered T memory stem cells and antigen targeted CAR-T therapy for virus infection and cancer diseases.